Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mona Sabharwal

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics - Open|February 15, 2018
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)Lisa Masucci, Jaclyn Beca, Mona Sabharwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Multiple Dimensions of Value: Evaluative Frameworks for New Cancer TherapiesMatthew C Cheung, Mona Sabharwal, Alexandra Chambers, et al.
Pharmacoeconomics|May 6, 2015
Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?Jeffrey S Hoch, Jaclyn Beca, Mona Sabharwal, et al.
Pharmacy World & Science : PWS|January 24, 2007
The effect of pharmacist education on asthma treatment plans for simulated patientsLisa Dolovich, Mona Sabharwal, Karen Agro, et al.
The Lancet. Oncology|May 13, 2017
Engaging specialist oncologists in the assessment of oncology drugs in CanadaWilliam Kenneth Evans, Mona Sabharwal, Anthony Fields, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|May 18, 2011
Proceedings from a symposium of the Canadian Association of Population Therapeutics--2010 annual conferenceScott Gavura, Angela Rocchi, Mona Sabharwal, et al.
ESMO Open|December 7, 2017
Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?Matthew C Cheung, Kelvin K W Chan, Mona Sabharwal, et al.
Cancer Medicine|May 28, 2019
The impact of pricing strategy on the costs of oral anti-cancer drugsJudy Truong, Kelvin K W Chan, Helen Mai, et al.
Cancer|June 23, 2017
The impact of cancer drug wastage on economic evaluationsJudy Truong, Matthew C Cheung, Helen Mai, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
An evaluation framework for funding drugs for rare diseasesEric Winquist, Chaim M Bell, Joe T R Clarke, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics - Open|February 15, 2018
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)Lisa Masucci, Jaclyn Beca, Mona Sabharwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Multiple Dimensions of Value: Evaluative Frameworks for New Cancer TherapiesMatthew C Cheung, Mona Sabharwal, Alexandra Chambers, et al.
Pharmacoeconomics|May 6, 2015
Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?Jeffrey S Hoch, Jaclyn Beca, Mona Sabharwal, et al.
Pharmacy World & Science : PWS|January 24, 2007
The effect of pharmacist education on asthma treatment plans for simulated patientsLisa Dolovich, Mona Sabharwal, Karen Agro, et al.
The Lancet. Oncology|May 13, 2017
Engaging specialist oncologists in the assessment of oncology drugs in CanadaWilliam Kenneth Evans, Mona Sabharwal, Anthony Fields, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|May 18, 2011
Proceedings from a symposium of the Canadian Association of Population Therapeutics--2010 annual conferenceScott Gavura, Angela Rocchi, Mona Sabharwal, et al.
ESMO Open|December 7, 2017
Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?Matthew C Cheung, Kelvin K W Chan, Mona Sabharwal, et al.
Cancer Medicine|May 28, 2019
The impact of pricing strategy on the costs of oral anti-cancer drugsJudy Truong, Kelvin K W Chan, Helen Mai, et al.
Cancer|June 23, 2017
The impact of cancer drug wastage on economic evaluationsJudy Truong, Matthew C Cheung, Helen Mai, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
An evaluation framework for funding drugs for rare diseasesEric Winquist, Chaim M Bell, Joe T R Clarke, et al.
Pageof 2